William Rieflin

William Rieflin serves as Executive Chairman at NGM Biopharmaceuticals. He is an Angel Investor. He also serves as Executive at 2M Companies. He also serves a Board Member at NGM Biopharmaceuticals. He brings several years of industry experience to NGM. Most recently, he was President of XenoPort, Inc. (Nasdaq: XNPT) and currently serves on XenoPort's Board of Directors. Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik, Inc. (Nasdaq: TLRK), which was acquired by Amgen, Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School. He is a board member of Xenoport. Rieflin is Board Member at Flexus Biosciences and Anacor Pharmaceuticals.